查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1822388

2032 年登革熱疫苗市場預測：按產品、疫苗類型、佐劑、給藥途徑、分銷管道、最終用戶和地區進行的全球分析

Dengue Vaccine Market Forecasts to 2032 - Global Analysis By Product (Dengvaxia, Qdenga, and Other Pipeline Candidates), Vaccine Type, Treatment Adjuncts, Route of Administration, Distribution Channel, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球登革熱疫苗市場預計在 2025 年達到 4.8961 億美元，到 2032 年將達到 13.5891 億美元，預測期內複合年成長率為 15.7%。

登革熱疫苗是預防登革熱（一種蚊媒病毒性疾病）的處方免疫接種。疫苗能夠引發免疫反應，使人體產生保護性抗體，進而抵抗登革熱病毒。這些疫苗的主要目的是最大限度地降低感染風險，減輕病情嚴重程度，並避免住院。這些疫苗在疫情控制中發揮重要作用，尤其是在登革熱構成重大健康挑戰的登革熱流行地區。

公眾健康意識不斷增強

各國政府和非政府組織正在加強登革熱預防教育工作，尤其是在登革熱流行地區。數位平台和行動醫療應用程式正被用於傳播疫苗訊息和追蹤疫苗接種覆蓋率。隨著都市化和氣候變遷擴大蚊子棲息地，預防​​措施變得更加迫切。監測和診斷領域的技術創新使得早期發現和有針對性的疫苗接種策略成為可能。這種意識的提高正在推動對可靠且可及的登革熱疫苗的需求，以滿足不同人群的需求。

安全性和有效性問題

由於擔心疫苗安全性以及不同血清型疫苗療效的差異，疫苗在某些地區的推廣速度有所放緩。監管機構呼籲進行大規模臨床試驗，以檢驗疫苗的長期療效，尤其是兒童和老年族群。四種登革熱病毒株的複雜性對免疫抗原性一致性提出了挑戰。不利事件監測系統正在升級，以確保上市後監測和透明度。人工智慧臨床分析等新技術正在幫助完善療效模型，但公眾的懷疑仍然是一個障礙。這些因素導致一些國家採取謹慎的推廣策略，市場滲透速度緩慢。

下一代疫苗的開發

mRNA平台和重組DNA技術的進步使得免疫反應更具針對性和持久性。研究機構和生物技術公司正在合作開發適用於熱帶氣候的耐熱製劑。人工智慧和生物資訊學正在加速抗原設計和測試模擬，縮短開發時間。各國政府正在提供津貼和加速核准，以支持該領域的創新。隨著全球衛生重點轉向疫情防範，登革熱疫苗研發正獲得策略性發展動能。

經濟限制

負擔能力仍然是一個重大障礙，尤其是在低收入和高負擔地區。有限的醫療預算和相互競爭的優先事項往往會延遲疫苗的採購和分配。登革熱疫苗等複雜生技藥品的高昂製造成本影響了定價策略。供應鏈效率低和低溫運輸需求進一步加劇了偏遠地區的物流。模組化和分散式製造的新興趨勢旨在降低成本並改善可及性。如果沒有持續的資金籌措和國際支持，市場擴張可能會不均衡，並且容易受到經濟衝擊的影響。

COVID-19的影響

疫情擾亂了疫苗臨床試驗，並轉移了登革熱疫苗接種計畫的資源。封鎖和旅行限制推遲了現場測試和監管審查，從而推遲了產品上市。然而，新冠疫情加速了數位醫療的普及，包括遠端試驗監控和基於人工智慧的數據收集。疫情期間建立的緊急使用框架目前正在適應登革熱疫苗的核准。後疫情時代策略強調韌性供應鏈和綜合疾病監測系統，其中將登革熱作為優先事項。

預測期內，登革熱疫苗市場預計將成為最大的市場

由於監管部門的核准和完善的全球分銷網路，預計登革熱疫苗市場將在預測期內佔據最大市場佔有率。登革熱疫苗是唯一獲得廣泛許可的疫苗，已在多個國家（主要在亞洲和拉丁美洲）投入使用。正在進行的上市後研究正在改善其風險-效益狀況，尤其對於血清陽性族群。低溫運輸物流和數位追蹤技術的進步正在提高疫苗的可用性和可靠性。與公共衛生機構的夥伴關係正在擴大登革熱疫苗在學校免疫接種計畫中的覆蓋率。儘管過去存在爭議，但Dengvaxia強大的市場影響力和基礎設施支撐了其市場領先地位。

預測期內腸外藥物市場將以最高複合年成長率成長

預計在預測期內，腸外疫苗領域將達到最高成長率。注射劑可精準給藥，並融入現有的醫療保健工作流程。無針注射器和微陣列貼片等創新技術正在提高患者依從性並縮短給藥時間。低溫運輸最佳化和智慧包裝技術使疫苗腸外給藥在偏遠地區更可行。由於下一代登革熱候選疫苗的吸收特性穩定，臨床試驗越來越傾向腸外給藥。隨著醫療保健系統的現代化，腸外給藥正成為大規模疫苗接種的首選途徑。

比最大的地區

預計亞太地區將在預測期內佔據最大的市場佔有率。印度、印尼和菲律賓等國家正在透過政府資助的宣傳活動擴大疫苗接種計畫。對生物技術基礎設施和本地製造業的投資正在減少對進口的依賴。行動醫療平台和人工智慧驅動的疾病地圖繪製正在提高疫苗部署的效率。全球製藥公司與區域參與者之間的策略聯盟正在加速技術轉移和監管協調。

複合年成長率最高的地區：

在預測期內，北美預計將憑藉其尖端研發和積極的監管支持，實現最高的複合年成長率。美國和加拿大正在大力投資疫苗創新，包括基於mRNA的登革熱候選疫苗。人工智慧和機器學習正在整合到臨床試驗設計和即時療效監測中。監管機構正在簡化熱帶疾病疫苗的核准途徑，以加快疫苗的上市速度。官民合作關係正在資助與全球擴張一致的先進生產和分銷模式。隨著氣候變遷導致美國南部登革熱風險增加，北美正逐漸成為關鍵的成長前線。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球登革熱疫苗市場（按產品）

  • 登革熱疫苗
  • 庫登加
  • 其他產品

6. 全球登革熱疫苗市場（依疫苗類型）

  • 減毒活疫苗
  • DNA疫苗
  • 嵌合體減毒活疫苗
  • 核酸疫苗
  • 去活化疫苗
  • 次單元/VLP疫苗

7. 全球登革熱疫苗市場（按輔助治療劑）

  • 利尿劑
  • 抗過敏藥物
  • 支持性護理
  • 抗凝血劑

8. 全球登革熱疫苗市場（依給藥途徑）

  • 口服
  • 腸外

9. 全球登革熱疫苗市場（依分銷管道）

  • 公共疫苗接種計劃
  • 醫院藥房
  • 私人診所和醫院
  • 旅行診所
  • 零售藥局
  • 網路藥局

10. 全球登革熱疫苗市場（依最終用戶）

  • 兒童（9至16歲）
  • 成人（17歲以上）
  • 居家照護環境
  • 旅行者和軍事人員
  • 政府和公共衛生機構
  • 醫院和專科診所
  • 其他最終用戶

11. 全球登革熱疫苗市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • Sanofi
  • Medigen Vaccine Biologics Corp.
  • Takeda Pharmaceutical Company
  • Biological E. Limited
  • GlaxoSmithKline（GSK）
  • Serum Institute of India
  • Bharat Biotech
  • Vabiotech
  • Merck & Co.
  • Panacea Biotec
  • F. Hoffmann-La Roche Ltd.
  • BioNet-Asia Co. Ltd.
  • Novartis AG
  • Instituto Butantan
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC31142

According to Stratistics MRC, the Global Dengue Vaccine Market is accounted for $489.61 million in 2025 and is expected to reach $1358.91 million by 2032 growing at a CAGR of 15.7% during the forecast period. A dengue vaccine is a preventive immunization formulated to safeguard people from dengue fever, a viral illness transmitted by mosquitoes. By triggering an immune response, it enables the body to generate protective antibodies that help defend against the dengue virus. Its primary purpose is to minimize infection risks, reduce disease intensity, and prevent hospitalizations. This vaccine plays a vital role in controlling outbreaks, especially in dengue-endemic areas where the disease poses significant health challenges.

Market Dynamics:

Driver:

Growing public health awareness

Governments and NGOs are intensifying education efforts around dengue prevention, especially in endemic regions. Digital platforms and mobile health apps are being leveraged to disseminate vaccine information and track immunization coverage. As urbanization and climate change expand mosquito habitats, the urgency for preventive measures is rising. Technological innovations in surveillance and diagnostics are enabling earlier detection and targeted vaccination strategies. This growing consciousness is fostering demand for reliable and accessible dengue vaccines across diverse populations.

Restraint:

Safety and efficacy concerns

Concerns over vaccine safety and variable efficacy across serotypes are slowing adoption in certain regions. Regulatory bodies require extensive clinical trials to validate long-term outcomes, especially for pediatric and elderly populations. The complexity of dengue's four viral strains poses challenges for consistent immunogenicity. Adverse event monitoring systems are being upgraded to ensure post-marketing surveillance and transparency. Emerging technologies like AI-driven trial analytics are helping refine efficacy models, but public skepticism remains a hurdle. These factors contribute to cautious rollout strategies and delayed market penetration in some countries.

Opportunity:

Development of next-generation vaccines

Advances in mRNA platforms and recombinant technologies are enabling more targeted and durable immune responses. Research institutions and biotech firms are collaborating on thermostable formulations suitable for tropical climates. AI and bioinformatics are accelerating antigen design and trial simulations, reducing development timelines. Governments are offering grants and fast-track approvals to support innovation in this space. As global health priorities shift toward pandemic preparedness, dengue vaccine R&D is gaining strategic momentum.

Threat:

Economic constraints

Affordability remains a major barrier, particularly in low-income and high-burden regions. Limited healthcare budgets and competing priorities often delay vaccine procurement and distribution. Manufacturing costs for complex biologics like dengue vaccines are high, impacting pricing strategies. Supply chain inefficiencies and cold chain requirements further strain logistics in remote areas. Emerging trends in modular production and decentralized manufacturing aim to reduce overheads and improve access. Without sustained funding and international support, market expansion may be uneven and vulnerable to economic shocks.

Covid-19 Impact

The pandemic disrupted vaccine trials and diverted resources away from dengue immunization programs. Lockdowns and travel restrictions delayed field studies and regulatory reviews, slowing product launches. However, Covid-19 accelerated digital health adoption, including remote trial monitoring and AI-based data collection. Emergency use frameworks introduced during the pandemic are now being adapted for dengue vaccine approvals. Post-Covid strategies emphasize resilient supply chains and integrated disease surveillance systems that include dengue as a priority.

The dengvaxia segment is expected to be the largest during the forecast period

The dengvaxia segment is expected to account for the largest market share during the forecast period, due to its established regulatory approvals and global distribution footprint. It remains the only widely licensed dengue vaccine with multi-country deployment, especially in Asia and Latin America. Continuous post-marketing studies are refining its risk-benefit profile, particularly for seropositive individuals. Technological upgrades in cold chain logistics and digital tracking are enhancing its reach and reliability. Partnerships with public health agencies are expanding its coverage in school-based immunization programs. Despite past controversies, Dengvaxia's entrenched presence and infrastructure support its leading market position.

The parenteral segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the parenteral segment is predicted to witness the highest growth rate, driven by their proven delivery efficiency and immunogenicity. Injectable formats offer precise dosing and are compatible with existing healthcare workflows. Innovations in needle-free injectors and microarray patches are improving patient compliance and reducing administration time. Cold chain optimization and smart packaging technologies are making parenteral vaccines more viable in remote settings. Clinical trials are increasingly favoring parenteral delivery for next-gen dengue candidates due to consistent absorption profiles. As healthcare systems modernize, parenteral formats are becoming the preferred choice for mass immunization drives.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share propelled by high disease prevalence and robust public health initiatives. Countries like India, Indonesia, and the Philippines are scaling up vaccination programs through government-backed campaigns. Investments in biotech infrastructure and local manufacturing are reducing dependency on imports. Mobile health platforms and AI-driven disease mapping are enhancing vaccine deployment efficiency. Strategic collaborations between global pharma firms and regional players are accelerating technology transfer and regulatory harmonization.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by cutting-edge R&D and proactive regulatory support. The U.S. and Canada are investing heavily in vaccine innovation, including mRNA-based dengue candidates. AI and machine learning are being integrated into clinical trial design and real-time efficacy monitoring. Regulatory agencies are streamlining approval pathways for tropical disease vaccines, encouraging faster market entry. Public-private partnerships are funding advanced manufacturing and distribution models tailored for global deployment. As climate change increases dengue risk in southern U.S. regions, North America is emerging as a key growth frontier.

Key players in the market

Some of the key players profiled in the Dengue Vaccine Market include Sanofi, Medigen Vaccine Biologics Corp., Takeda Pharmaceutical Company, Biological E. Limited, GlaxoSmithKline (GSK), Serum Institute of India, Bharat Biotech, Vabiotech, Merck & Co., Panacea Biotec, F. Hoffmann-La Roche Ltd., BioNet-Asia Co. Ltd., Novartis AG, Instituto Butantan, and Teva Pharmaceutical Industries Ltd.

Key Developments:

In Sepetember 2025, Medigen Vaccine Biologics Corp (MVC) has signed a regional distribution agreement with the pharmaceutical company Substipharm Biologics to expand the market reach of enterovirus vaccine products in Southeast Asia. The two companies have finalized an exclusive distribution agreement for ENVACGEN(R) Enterovirus A71 (EV-A71) vaccine in Vietnam as the first country of launch.

In August 2025, Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc.. This acquisition strengthens Sanofi's early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer's disease. In addition, the acquisition of Vigil's preclinical pipeline will further strengthen Sanofi's research in various neurodegenerative diseases.

Products Covered:

  • Dengvaxia
  • Qdenga
  • Other Pipeline Candidates

Vaccine Types Covered:

  • Live Attenuated Vaccine
  • DNA Vaccine
  • Chimeric Live Attenuated Vaccine
  • Nucleic Acid-Based Vaccine
  • Inactivated Vaccine
  • Subunit/VLP Vaccine

Treatment Adjuncts Covered:

  • Diuretics
  • Anti-Allergic Agents
  • Supportive Therapies
  • Blood Thinners

Route of Administrations Covered:

  • Oral
  • Parenteral

Distribution Channels Covered:

  • Public Immunization Programs
  • Hospital Pharmacy
  • Private Clinics & Hospitals
  • Travel Clinics
  • Retail Pharmacy
  • Online Pharmacy

End Users Covered:

  • Pediatrics (9-16 years)
  • Adults (>=17 years)
  • Homecare Settings
  • Travelers & Military Personnel
  • Government & Public Health Agencies
  • Hospitals & Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dengue Vaccine Market, By Product

  • 5.1 Introduction
  • 5.2 Dengvaxia
  • 5.3 Qdenga
  • 5.4 Other Pipeline Candidates

6 Global Dengue Vaccine Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 Live Attenuated Vaccine
  • 6.3 DNA Vaccine
  • 6.4 Chimeric Live Attenuated Vaccine
  • 6.5 Nucleic Acid-Based Vaccine
  • 6.6 Inactivated Vaccine
  • 6.7 Subunit/VLP Vaccine

7 Global Dengue Vaccine Market, By Treatment Adjuncts

  • 7.1 Introduction
  • 7.2 Diuretics
  • 7.3 Anti-Allergic Agents
  • 7.4 Supportive Therapies
  • 7.5 Blood Thinners

8 Global Dengue Vaccine Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parenteral

9 Global Dengue Vaccine Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Public Immunization Programs
  • 9.3 Hospital Pharmacy
  • 9.4 Private Clinics & Hospitals
  • 9.5 Travel Clinics
  • 9.6 Retail Pharmacy
  • 9.7 Online Pharmacy

10 Global Dengue Vaccine Market, By End User

  • 10.1 Introduction
  • 10.2 Pediatrics (9-16 years)
  • 10.3 Adults (>=17 years)
  • 10.4 Homecare Settings
  • 10.5 Travelers & Military Personnel
  • 10.6 Government & Public Health Agencies
  • 10.7 Hospitals & Specialty Clinics
  • 10.8 Other End Users

11 Global Dengue Vaccine Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Sanofi
  • 13.2 Medigen Vaccine Biologics Corp.
  • 13.3 Takeda Pharmaceutical Company
  • 13.4 Biological E. Limited
  • 13.5 GlaxoSmithKline (GSK)
  • 13.6 Serum Institute of India
  • 13.7 Bharat Biotech
  • 13.8 Vabiotech
  • 13.9 Merck & Co.
  • 13.10 Panacea Biotec
  • 13.11 F. Hoffmann-La Roche Ltd.
  • 13.12 BioNet-Asia Co. Ltd.
  • 13.13 Novartis AG
  • 13.14 Instituto Butantan
  • 13.15 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Dengue Vaccine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Dengue Vaccine Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Dengue Vaccine Market Outlook, By Dengvaxia (2024-2032) ($MN)
  • Table 4 Global Dengue Vaccine Market Outlook, By Qdenga (2024-2032) ($MN)
  • Table 5 Global Dengue Vaccine Market Outlook, By Other Pipeline Candidates (2024-2032) ($MN)
  • Table 6 Global Dengue Vaccine Market Outlook, By Vaccine Type (2024-2032) ($MN)
  • Table 7 Global Dengue Vaccine Market Outlook, By Live Attenuated Vaccine (2024-2032) ($MN)
  • Table 8 Global Dengue Vaccine Market Outlook, By DNA Vaccine (2024-2032) ($MN)
  • Table 9 Global Dengue Vaccine Market Outlook, By Chimeric Live Attenuated Vaccine (2024-2032) ($MN)
  • Table 10 Global Dengue Vaccine Market Outlook, By Nucleic Acid-Based Vaccine (2024-2032) ($MN)
  • Table 11 Global Dengue Vaccine Market Outlook, By Inactivated Vaccine (2024-2032) ($MN)
  • Table 12 Global Dengue Vaccine Market Outlook, By Subunit/VLP Vaccine (2024-2032) ($MN)
  • Table 13 Global Dengue Vaccine Market Outlook, By Treatment Adjuncts (2024-2032) ($MN)
  • Table 14 Global Dengue Vaccine Market Outlook, By Diuretics (2024-2032) ($MN)
  • Table 15 Global Dengue Vaccine Market Outlook, By Anti-Allergic Agents (2024-2032) ($MN)
  • Table 16 Global Dengue Vaccine Market Outlook, By Supportive Therapies (2024-2032) ($MN)
  • Table 17 Global Dengue Vaccine Market Outlook, By Blood Thinners (2024-2032) ($MN)
  • Table 18 Global Dengue Vaccine Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 19 Global Dengue Vaccine Market Outlook, By Oral (2024-2032) ($MN)
  • Table 20 Global Dengue Vaccine Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 21 Global Dengue Vaccine Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 22 Global Dengue Vaccine Market Outlook, By Public Immunization Programs (2024-2032) ($MN)
  • Table 23 Global Dengue Vaccine Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
  • Table 24 Global Dengue Vaccine Market Outlook, By Private Clinics & Hospitals (2024-2032) ($MN)
  • Table 25 Global Dengue Vaccine Market Outlook, By Travel Clinics (2024-2032) ($MN)
  • Table 26 Global Dengue Vaccine Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
  • Table 27 Global Dengue Vaccine Market Outlook, By Online Pharmacy (2024-2032) ($MN)
  • Table 28 Global Dengue Vaccine Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global Dengue Vaccine Market Outlook, By Pediatrics (9-16 years) (2024-2032) ($MN)
  • Table 30 Global Dengue Vaccine Market Outlook, By Adults (>=17 years) (2024-2032) ($MN)
  • Table 31 Global Dengue Vaccine Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 32 Global Dengue Vaccine Market Outlook, By Travelers & Military Personnel (2024-2032) ($MN)
  • Table 33 Global Dengue Vaccine Market Outlook, By Government & Public Health Agencies (2024-2032) ($MN)
  • Table 34 Global Dengue Vaccine Market Outlook, By Hospitals & Specialty Clinics (2024-2032) ($MN)
  • Table 35 Global Dengue Vaccine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.